Boulder, CO, United States
Boulder, CO, United States

Time filter

Source Type

Patent
Array BioPharma | Date: 2017-03-22

A compound which is 6-chloro-7-(4-(4-chloro-2-methoxyphenethylcarbamoyl)-phenoxy)chroman-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. Said compound is either a racemic mixture or a single enantiomer, preferably Enantiomer 2 of 6-chloro-7-(4-(4-chloro-2-methoxyphenethylcarbamoyl)phenoxy)chroman-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, in particular its sodium salt. Said compound for use in treating an immunologic disorder in a mammal.


Patent
VentiRx Pharmaceuticals and Array BioPharma | Date: 2017-04-26

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.


Compounds of Formula I: and salts thereof in which R^(1), R^(2), R^(3), R^(4), X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.


Patent
Array BioPharma | Date: 2017-01-09

Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R^(2), R^(2a), R^(3), R^(3a), and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.


Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal.


Methods for treating a disease or disorder selected from pain, cancer, inflammation, neurodegenerative disease, Typanosoma cruzi infection and osteolytic disease in a mammal, which comprise administering to said mammal a therapeutically effective amount of a compound of Formula I in which R^(1), R^(2), R^(3), R^(4), X, Y and n have the meanings given in the specification.


Compounds of Formula I: and salts thereof in which R^(1), R^(2), R^(3), R^(4), X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.


Patent
Array BioPharma | Date: 2017-01-09

Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R^(2), R^(2a), R^(3), R^(3a), and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.


Methods for treating a disease or disorder selected from pain, cancer, inflammation, neurodegenerative disease, Typanosoma cruzi infection and osteolytic disease in a mammal, which comprise administering to said mammal a therapeutically effective amount of a compound of Formula I in which R^(1), R^(2), R^(3), R^(4), X, Y and n have the meanings given in the specification.


A novel crystalline form of (S)N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection are disclosed. In some embodiments, the novel crystalline form comprises a stable polymorph of (S)N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate. The present invention is further directed to a process for the preparation of the novel crystalline form.

Loading Array BioPharma collaborators
Loading Array BioPharma collaborators